AU2007305138A1 - Epoxide inhibitors of cysteine proteases - Google Patents

Epoxide inhibitors of cysteine proteases Download PDF

Info

Publication number
AU2007305138A1
AU2007305138A1 AU2007305138A AU2007305138A AU2007305138A1 AU 2007305138 A1 AU2007305138 A1 AU 2007305138A1 AU 2007305138 A AU2007305138 A AU 2007305138A AU 2007305138 A AU2007305138 A AU 2007305138A AU 2007305138 A1 AU2007305138 A1 AU 2007305138A1
Authority
AU
Australia
Prior art keywords
compound
group
infection
pct
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007305138A
Other languages
English (en)
Inventor
Matthew S. Bogyo
Amir M. Sadaghiani
Steven Verhelst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of AU2007305138A1 publication Critical patent/AU2007305138A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/04—Compounds containing oxirane rings containing only hydrogen and carbon atoms in addition to the ring oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/48—Compounds containing oxirane rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
AU2007305138A 2006-06-13 2007-06-13 Epoxide inhibitors of cysteine proteases Abandoned AU2007305138A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81363906P 2006-06-13 2006-06-13
US60/813,639 2006-06-13
PCT/US2007/071145 WO2008042480A2 (en) 2006-06-13 2007-06-13 Epoxide inhibitors of cysteine proteases

Publications (1)

Publication Number Publication Date
AU2007305138A1 true AU2007305138A1 (en) 2008-04-10

Family

ID=39269056

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007305138A Abandoned AU2007305138A1 (en) 2006-06-13 2007-06-13 Epoxide inhibitors of cysteine proteases

Country Status (11)

Country Link
US (1) US8673904B2 (enExample)
EP (1) EP2029135A4 (enExample)
JP (1) JP2010500962A (enExample)
KR (1) KR20090029725A (enExample)
CN (1) CN101808634A (enExample)
AU (1) AU2007305138A1 (enExample)
BR (1) BRPI0712868A2 (enExample)
CA (1) CA2655139A1 (enExample)
IL (1) IL195782A0 (enExample)
RU (1) RU2009100878A (enExample)
WO (1) WO2008042480A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2921486B1 (en) 2009-08-07 2017-09-27 American Life Science Pharmaceuticals, Inc. Compositions and methods for treating beta-amyloid related diseases
US9345789B2 (en) 2009-12-18 2016-05-24 The Board Of Trustees Of The Leland Stanford Junior University Specific inhibitors and active site probes for legumain
US20140170653A1 (en) 2011-04-15 2014-06-19 Life Technologies Corporation Chemical ligation
US9403843B2 (en) 2012-02-01 2016-08-02 The Trustees Of Columbia University In The City Of New York Cysteine protease inhibitors and uses thereof
CN104211666B (zh) * 2013-05-31 2017-11-14 中国人民解放军军事医学科学院毒物药物研究所 2,3‑环氧丁二酰胺类化合物、其制备方法和用途
CN107151236B (zh) * 2016-03-03 2021-04-30 中国人民解放军军事医学科学院毒物药物研究所 一种2,3-环氧丁二酰衍生物及其制备方法和用途
EP4324460A3 (en) 2017-09-15 2024-04-24 Dyve Biosciences, Inc. Sodium bicarbonate for use in the treatment of gout and related disorders
US20190134219A1 (en) * 2017-09-15 2019-05-09 Ampersand Biopharmaceuticals, Inc. Inhibition of spontaneous metastasis via protein inhibitors of cysteine proteases
CN110241438A (zh) * 2018-03-08 2019-09-17 天津大学 泡沫铜担载钯铜合金纳米笼催化剂及其制备方法
US11905249B2 (en) 2021-01-25 2024-02-20 Jackson State University Covalent inhibitors of equine encephalitis virus
KR20230165715A (ko) 2022-05-27 2023-12-05 서울대학교산학협력단 기생충 감염증의 예방 또는 치료용 약학 조성물
AU2024230810A1 (en) * 2023-03-02 2025-09-04 Kyoto University Radioactive metal-labeled antibody, radioactive pharmaceutical, and compound

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1469797A (en) 1974-11-07 1977-04-06 Pfizer Ltd Antibacterial cephalosporin derivatives
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
JPS55115878A (en) * 1979-02-27 1980-09-06 Taisho Pharmaceut Co Ltd Epoxysuccinic acid derivative
JPS55153778A (en) * 1979-05-17 1980-11-29 Taisho Pharmaceut Co Ltd Epoxysuccinylamino acid derivative
JPS57169478A (en) 1981-04-10 1982-10-19 Nippon Chemiphar Co Ltd Piperazine derivative
JPS6276A (ja) 1985-03-26 1987-01-06 Toyo Jozo Co Ltd 酵素阻害性新規物質
JP2808877B2 (ja) 1990-09-29 1998-10-08 大正製薬株式会社 エポキシスクシナム酸誘導体およびその中間体
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5556853A (en) 1993-10-29 1996-09-17 Takeda Chemical Industries, Ltd. Epoxysuccinic acid derivatives
JPH08104683A (ja) * 1993-10-29 1996-04-23 Takeda Chem Ind Ltd エポキシコハク酸誘導体
JPH08104684A (ja) * 1994-05-31 1996-04-23 Takeda Chem Ind Ltd エポキシコハク酸関連化合物
CA2190151A1 (en) 1994-05-31 1995-12-07 Shigetoshi Tsubotani Epoxysuccinic acid derivatives, their production and use
AU697565B2 (en) * 1995-12-12 1998-10-08 Taiho Pharmaceutical Co., Ltd. Epoxysuccinamide derivative or salt thereof and medicine comprising the same
EP0921122B1 (en) * 1997-04-18 2003-05-21 Taiho Pharmaceutical Company, Limited Epoxysuccinamide derivatives or salts thereof
JPH11263783A (ja) * 1998-01-09 1999-09-28 Taisho Pharmaceut Co Ltd エポキシスクシナム酸誘導体
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
AU2002232681A1 (en) 2000-11-10 2002-05-21 The Regents Of The Univeristy Of California Activity-dependent cysteine protease profiling reagent
US7247684B2 (en) * 2001-09-12 2007-07-24 Dow Global Technologies Inc. Network polymers comprising epoxy-terminated esters
US20030212003A1 (en) 2002-02-14 2003-11-13 Hermann Lubbert Cathepsin Y for the development of a medicament for the treatment of pain
US20060154325A1 (en) * 2005-01-10 2006-07-13 Matthew Bogyo Synthesis of epoxide based inhibitors of cysteine proteases

Also Published As

Publication number Publication date
EP2029135A4 (en) 2011-08-17
BRPI0712868A2 (pt) 2013-05-07
KR20090029725A (ko) 2009-03-23
EP2029135A2 (en) 2009-03-04
WO2008042480A2 (en) 2008-04-10
JP2010500962A (ja) 2010-01-14
WO2008042480A3 (en) 2008-08-14
US20080176841A1 (en) 2008-07-24
IL195782A0 (en) 2009-09-01
RU2009100878A (ru) 2010-07-20
US8673904B2 (en) 2014-03-18
CA2655139A1 (en) 2008-04-10
CN101808634A (zh) 2010-08-18

Similar Documents

Publication Publication Date Title
US8673904B2 (en) Epoxide inhibitors of cysteine proteases
JP7325483B6 (ja) 免疫調節剤としての１，２，４－オキサジアゾールおよびチアジアゾール化合物
RU2450016C2 (ru) Пептидные эпоксикетоны для ингибирования протеасомы
KR101474405B1 (ko) 방법 및 중간체
ES2383749T3 (es) Derivados de diamina
KR100659651B1 (ko) 시클릭 아미드 유도체
JP2012525392A (ja) 方法および中間体
TW201345915A (zh) 作為蛋白酶抑制劑之螺環腈類
SK149798A3 (en) Carboxamide derivatives of pyrrolidine, piperidine and hexahydroazepine for the treatment of thrombosis disorders
JPH08504815A (ja) 環状スルホン含有レトロウイルスプロテアーゼ阻害物質
JP2017523995A (ja) Ｍｅｔａｐ−２阻害剤としてのピロリジノン誘導体
US8344002B2 (en) Compound having β-secretase inhibitory activity
DE19850131A1 (de) Chromenon- und Chromanonderivate
JPH05294916A (ja) トリフルオロメチル含有プソイドペプチド
JP2000500432A (ja) 環状ペプチド誘導体
CN114667136A (zh) Trofinetide的组合物
JPH09509657A (ja) 中間体および製造のための方法
JPH09295996A (ja) システインプロテアーゼ阻害化合物
JPH08259594A (ja) トリフルオロメチル置換２−アザビシクロオクタンを含有する新規アシル化プソイドペプチド
NZ574550A (en) An aminoisoquinoline thrombin inhibitor with improved bioavailability
CA2166372A1 (en) Pseudopeptides having a trifluoromethyl-substituted 2-azabicyclooctane
HRP980112A2 (en) Hiv protease inhibitors

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application